reports
Transgene and NEC Present New Data Confirming Clinical Proof of Princi...
Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024 Compelling 24.1-month median follow-up data presented at SITC 2024 showed that all patients treated with TG4050 after completion of an adjuvant standard of care remain disease-free TG4050 induced specific and sustained immune responses. A Phase II part is now enrolling patients internationally to build on this promising outcome Strasbourg, France & Tokyo, Japan, November 7, 2024, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), a b...
Transgene et NEC présentent de nouvelles données confirmant la preuve ...
Transgene et NEC présentent de nouvelles données confirmant la preuve de principe clinique pour son vaccin thérapeutique TG4050, dans les cancers de la tête et du cou au SITC 2024 Les données de suivi médian à 24,1 mois présentées au SITC 2024 montrent que tous les patients traités avec TG4050 en situation adjuvante après chirurgie et chimiothérapie standard sont toujours en rémission clinique et sans récidive TG4050 induit des réponses immunitaires persistantes et spécifiques. Une partie Phase II inclut actuellement des patients dans plusieurs pays pour confirmer ces données prometteu...
Transgene Reports Business, Pipeline and Financial Update for Q3 2024
Transgene Reports Business, Pipeline and Financial Update for Q3 2024 TG4050: Promising Phase I data to be presented at SITC 2024 providing clinical proof of principle in adjuvant head and neck cancer setting Financial visibility confirmed into Q4 2025 Strasbourg, France, November 7, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today provides its business update and financial position for the quarter ending September 30, 2024. Key events and upcoming milestones ...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
Transgene and ProBioGen Join Forces to Advance Individualized Cancer V...
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development Strasbourg (France), Berlin (Germany), November 5, 2024, 7:30 a.m. CET—Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and ProBioGen, a leading CDMO in biologics, vaccines and viral vectors, announce that the companies have entered into a license agreement for ProBioGen’s AGE1.CR.pIX® suspension cell line. This partnership aims to add value by combining ProBioGen’s specific production technology with the manufacturing ...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jean Danjou
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
TNG TRANSGENE SA
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
01913 PRADA S.P.A.
NDA AURUBIS AG
MONC MONCLER SPA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
JST JOST WERKE AG
- Jean Danjou
- Thomas Zlowodzki
MC LVMH MOET HENNESSY LOUIS VUITTON SE
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
TNG TRANSGENE SA
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
01913 PRADA S.P.A.
NDA AURUBIS AG
MONC MONCLER SPA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
JST JOST WERKE AG
- Martial Descoutures
- Oussema Denguir
Transgene : TG4001 did not achieve its phase II primary endpoint
>Failure of TG4001 - We learned this morning that the first results of the phase II trial evaluating TG4001 in combination with Merck’s Bavencio did not achieve its primary endpoint in patients with recurrent or metastatic HP16-positive cervical and anogenital tumours (caused by the papillomavirus). At this stage we have no details on these results or the data. We can underline two aspects: it appears that a sub-group of patients showed a positive “trend” in term...
- Martial Descoutures
- Oussema Denguir
Transgene : TG4001 n’atteint pas son critère primaire en phase 2
>Echec de TG4001 - Nous apprenons ce matin que les premiers résultats de l’essai de phase 2 évaluant TG4001 en combinaison avec Bavencio de Merck KgaA n’a pas atteint son critère primaire chez des patients atteints de tumeurs du col de l’utérus et anogénitales HP16-positives (induit par le papillomavirus) récurrentes ou métastatiques. Nous n’avons, à ce stade, aucun détail sur ces résultats ni sur leur teneur. Nous pouvons souligner deux aspects : il semblerait q...
Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vacc...
Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers Top line data show that the randomized Phase II study of TG4001 in combination with avelumab versus avelumab alone in patients with recurrent or metastatic HPV16-positive cervical and anogenital tumors did not meet the primary objective of improvement in progression-free survival Pre-planned subgroup analysis showed a positive efficacy trend in favor of the TG4001 containing regimen in patients with cervical cancer Transgene will comp...
Transgene fait le point sur l’étude de Phase II du vaccin thérapeutiqu...
Transgene fait le point sur l’étude de Phase II du vaccin thérapeutique TG4001 dans les cancers du col de l’utérus et anogénitaux HPV16 positifs, récurrents ou métastatiques Les premiers résultats de l’essai de Phase II randomisé évaluant la combinaison de TG4001 avec avelumab versus avelumab seul chez des patients atteints de tumeurs du col de l’utérus et anogénitales HPV16-positives, récurrentes ou métastatiques, montrent que l’objectif principal (amélioration de la survie sans progression) n’a pas été atteint Une analyse de sous-groupes, prévue au protocole, a montré une tendance ...
Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024
Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024 Transgene will present median 24-month follow up data from patients enrolled in the Phase I trial evaluating the individualized cancer vaccine TG4050 in the adjuvant treatment of head and neck cancer Strasbourg, France, October 7, 2024, 8 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster highlighting median 24-month follow up from the ongoing randomized Phase I trial of its individualized therapeuti...
- Dominic Rose
- Naresh Chouhan
Transgene- TG4050 Advancing, New BT001 Data (TP EUR2.60 [3.20])
With TG4050, Transgene’s lead myvac platform candidate, advancing into phase II following positive results from the P1 trial, we now value the drug at €50m, with risk adj. peak sales of ~$220m. The company also reported positive data from part B of its P1 trial of BT001, which showed signs of disease control in a challenging patient group with advanced or metastatic solid tumours who had exhausted standard therapies. Following the €33m debt-to-equity conversion and removal of TG6002 from the pip...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Michael B. Schäfer
- Michael B. Schäfer
- Martial Descoutures
- Oussema Denguir
Transgene : A dense clinical calendar in the coming weeks
>Financial visibility out to Q4 2025 confirmed - Transgène yesterday evening reported its H1 2024 results which contained no major surprises. Operating income totalled € 3.4m (vs € 4.8m in H1 2023). R&D costs were stable at € 15.4m and the net loss was € 16.5m (vs -€ 15.9m in H1 2023).Transgene's cash position reached € 15.3m, resulting in as expected financial visibility out to Q4 2025. This financial visibility is made possible by the fact that Transgene has al...
- Martial Descoutures
- Oussema Denguir
Transgene : Un calendrier clinique chargé dans ces prochaines semaines
>Visibilité financière jusqu’au T4 2025 confirmée - Transgène publiait hier soir ses résultats financiers du S1 2024 qui se révèlent sans grande surprise. Les produits d’exploitations atteignent 3.4 M€ (vs 4.8 M€ au S1 2023). Les coûts de R&D sont stables à 15.4 M€ et la perte nette ressort à 16.5 M€ (vs -15.9 M€ au S1 2023).La position de trésorerie de Transgène atteint 15.3 M€ conduisant à avoir comme attendu une visibilité financière jusqu’au T4 2025. Cette vi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.